Abstract: Disclosed herein are phosphorus-containing actives, their use as actives for treating diseases, and a stereoselective process for preparing the same. Also disclosed herein are useful synthetic intermediates and processes for preparing the same.

Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

Abstract: A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof.

Abstract: In a process for preparing pentostatin, the improvement wherein reduction is performed on ketone prior to deprotection, comprising: a) reacting 3-(2-deoxy-3,5-di-O-p-toluoyl-b-D-erythro-pentofuranosyl)-6,7-dihydroimidazol [4,5-d][1,3] diazepin-8 (3H)-one with a ruthenium catalyst formed by the reaction of di-?-chlorobis[(p-cymene) chlororuthenium (II) and N-(arylsulfonyl)-1,2-diarylethylene diamine in a solvent; b) stopping the reaction in step a) by making the reaction medium alkaline; c) separating the mixture from step b) into combined organic layers and washing the reaction product from the combined organic layers with water, filtering, and evaporating solvent to provide a crude product, wherein the ratio of 8R vs 8S isomeric alcohol >100; d) purifying said crude product by chromatography; e) deprotecting the keto nucleoside in the crude product in methanol/sodium methoxide to obtain pentostatin; and f) purifying by recrystallizing pentostatin from methanol to remove inorganic and isomeric impurities.